As of November 6, 2026, RedHill Biopharma Ltd. is a publicly traded company (Nasdaq: RDHL); its largest reported holder is Alumni Capital LP, with 9.99% on Schedule 13G of October 20, 2025, then YA II PN, Ltd. (a Yorkville Advisors fund, per the filing) (9.9%) (Schedule 13G, October 20, 2025).
Is this your company?
About to sign with, pay or invest in RedHill Biopharma Ltd.? See the free Snapshot first.
Free to see. No signup.
Is RedHill Biopharma Ltd. a real, registered company?
- RedHill Biopharma Ltd. files with the SEC under CIK 1553846 (its SEC filings).
- Its shares are listed under the ticker RDHL on Nasdaq (SEC company record).
- Incorporated in L3; business address in Tel Aviv, L3, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under RedHill Biopharma Ltd. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names YA II PN, Ltd. (filed 2025-12-23).
Who are RedHill Biopharma Ltd.'s owners and officers?
RedHill Biopharma Ltd.: business address in Tel Aviv, L3; industry Pharmaceutical Preparations (F-1/A, 2026-01-22).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-02-05)
- : Executive Officer (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Executive Officer, Director (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Executive Officer (Form D, 2024-02-05)
- : Executive Officer (Form D, 2024-02-05)
- : Executive Officer (Form D, 2024-02-05)
- : Executive Officer (Form D, 2024-02-05)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2025-12-23 | Ya Ii Pn, LTD. | 9.9% |
| Schedule 13G, 2025-10-20 | Alumni Capital LP | 9.99% |
Questions about who owns RedHill Biopharma Ltd.
Who owns RedHill Biopharma Ltd.?
On this page, 2 holders' latest ownership filings report 5% or more of RedHill Biopharma Ltd.: Alumni Capital LP (9.99%, Schedule 13G, filed 2025-10-20) and Ya Ii Pn, LTD. (9.9%, Schedule 13G, filed 2025-12-23).
Who are the largest shareholders of RedHill Biopharma Ltd.?
By the share each holder's latest filing reports, the largest holders of RedHill Biopharma Ltd. on this page are Alumni Capital LP (9.99%) and Ya Ii Pn, LTD. (9.9%).
When did Alumni Capital LP buy into RedHill Biopharma Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Alumni Capital LP on this page is the Schedule 13G, filed 2025-10-20, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on RedHill Biopharma Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on RedHill Biopharma Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on RedHill Biopharma Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own RedHill Biopharma Ltd. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 441,350,000 shares (0.87% of shares outstanding) (Form 3, 2026-03-18).
- , the chief commercial officer and a director: 312,500,000 shares (0.61% of shares outstanding) (Form 3, 2026-03-18).
- , the chief business officer: 305,720,000 shares (0.60% of shares outstanding) (Form 3, 2026-03-18).
- , the chief financial officer: 277,560,000 shares (0.55% of shares outstanding) (Form 3, 2026-03-18).
- , the chief corp and bd officer: 276,810,000 shares (0.54% of shares outstanding) (Form 3, 2026-03-18).
Shares outstanding: 50,923,261,000 as of 2025-12-31, from the company's latest SEC cover page.
How much has RedHill Biopharma Ltd. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-02-05 | $10M | $10M |
| Form D, 2023-10-12 | $4.04M | $4.04M |
| Form D, 2023-08-07 | $2.70M | $2.70M |
Latest IPO step: RedHill Biopharma Ltd. amended its IPO registration (F-1/A, 2026-01-22).
IPO filings: F-1/A, 2026-01-22, F-1, 2025-12-31, F-1, 2025-06-25; ticker RDHL on Nasdaq Capital Market.
Keep reading
More on RedHill Biopharma Ltd. and the records around it.
RedHill Biopharma Ltd. elsewhere on the record
- 5%+ stake filings Dec 2025
Companies that share a holder
- Alumni Capital LP also filed stake reports on 12 other companies: reAlpha Tech Corp. (Nov 2026), Sports Entertainment Gaming Global Corp (Nov 2026), NEXALIN TECHNOLOGY, INC. (Aug 2026)
- YA II PN, Ltd. also filed stake reports on 13 other companies: Ives Ultra AI Opportunities Inc. (Oct 2026), Beneficient (Oct 2026), Optimi Health Corp. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/redhill-biopharma